secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACCENDRA HEALTH INC/VA/ (ACH)
CIK:        0000075252
Form:       8-K
Filed at:   2026-09-17T10:35:51+00:00
Accession:  0001104659-26-108405
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Accendra Health names Kenneth Gardner-Smith as next CEO; Scott Lloyd as Chief Commercial Officer
--------------------------------------------------------------------------------

- Gardner-Smith, Board member since Mar 2022, to assume CEO early Q4 2026; succeeds retiring Edward Pesicka.
- Offer Letter: $1.0M base salary, 130% target bonus, $6M equity grant (25% RSU, 25% PSU, 50% cash PSU), $650K sign-on bonus.
- Lloyd to become Chief Commercial Officer effective Oct 5, 2026; ex-Evergreen Nephrology, co-founder of Extrakare.
- Pesicka remains CEO until transition, then advisor; Gardner-Smith steps down from two board committees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/75252/000110465926108405/0001104659-26-108405-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/75252/000110465926108405/ach-20260916x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-108405

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer